Interleukin-6 (IL-6) and VEGF serum levels are increased in patients with colorectal cancer (CRC) and VEGF overexpression can be a useful prognostic factor. The aims of this study were (i) to compare serum IL-6 and VEGF between patients with CRC and controls, and (ii) to evaluate the relationship between serum VEGF and the expression of VEGF-1. Preoperative laboratory data from 36 patients (25 men, 11 women, median age 63, range 39-74 years) with stage I CRC (cases), and tissue microarray sections stained using anti-human VEGF (clone VG-1) were reviewed. Controls were 34 age- and sex-matched patients with benign colorectal diseases. Serum IL-6 and VEGF was measured using quantitative ELISA kit. The cut-off value was set at 6.5 and 235 pg/mL, respectively. The expression of VEGF was tested using a 4-grade scoring system, according to the degree of cytoplasmic staining, ranging from negative to intense staining. The sensitivity, specificity, positive and negative predictive value, likelihood ratio for positive and negative test (VEGF vs. IL-6) were 0.83 vs. 0.81, 0.85 vs. 0.88, 0.86 vs.0.88, 0.83 vs. 0.81, 5.67 vs. 6.85, and 0.20 vs. 0.22 (p=NS). The accuracy, pretest odds and pretest probability were 0.84, 1.041, and 0.51, respectively. A significant relationship between serum VEGF and VEGF-1 grade (R=0.51, p=0.002) was also observed. In this preliminary study, serum IL-6 and VEGF have similar usefulness in patients with CRC. The angiogenic activity of the tumor can safely be tested by measurements of both serum VEGF levels and grade of tumor tissue expression of VEGF-1.

Serum Interleukin-6, VEGF, and VEGF-1 Expression in Patients with Colorectal Cancer. A case-control study

LUMACHI, FRANCO;
2014

Abstract

Interleukin-6 (IL-6) and VEGF serum levels are increased in patients with colorectal cancer (CRC) and VEGF overexpression can be a useful prognostic factor. The aims of this study were (i) to compare serum IL-6 and VEGF between patients with CRC and controls, and (ii) to evaluate the relationship between serum VEGF and the expression of VEGF-1. Preoperative laboratory data from 36 patients (25 men, 11 women, median age 63, range 39-74 years) with stage I CRC (cases), and tissue microarray sections stained using anti-human VEGF (clone VG-1) were reviewed. Controls were 34 age- and sex-matched patients with benign colorectal diseases. Serum IL-6 and VEGF was measured using quantitative ELISA kit. The cut-off value was set at 6.5 and 235 pg/mL, respectively. The expression of VEGF was tested using a 4-grade scoring system, according to the degree of cytoplasmic staining, ranging from negative to intense staining. The sensitivity, specificity, positive and negative predictive value, likelihood ratio for positive and negative test (VEGF vs. IL-6) were 0.83 vs. 0.81, 0.85 vs. 0.88, 0.86 vs.0.88, 0.83 vs. 0.81, 5.67 vs. 6.85, and 0.20 vs. 0.22 (p=NS). The accuracy, pretest odds and pretest probability were 0.84, 1.041, and 0.51, respectively. A significant relationship between serum VEGF and VEGF-1 grade (R=0.51, p=0.002) was also observed. In this preliminary study, serum IL-6 and VEGF have similar usefulness in patients with CRC. The angiogenic activity of the tumor can safely be tested by measurements of both serum VEGF levels and grade of tumor tissue expression of VEGF-1.
2014
Targeting VEGF-mediated Tumor Angiogenesis in Cancer Therapy - Abstract Book
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/3162323
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact